SEC Form 4 · accession 0001638599-16-000693
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J. Regan
Officer — SVP, Chief Compliance Officer
Period of report
Feb 25, 2016
Accepted (ET)
Feb 29, 2016 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.98 | Feb 25, 2016 | A | 52,405 | A | Feb 26, 2016 | Feb 25, 2026 | Common Stock | 52,405 | 52,405 | D |
Explanation of responses
- F1Granted in lieu of cash bonus under 2015 bonus plan.